AR1001 slows cognitive decline by 31% in Alzheimer’s subgroup
The oral drug from AriBio missed significance in the overall group, leaving further trials and regulatory review central to any treatment path.

AriBio’s AR1001 slowed cognitive decline by 31% over one year among 604 early Alzheimer’s patients not taking other Alzheimer’s drugs, a Nov. 18 Guardian Health report said.
The finding matters because Alzheimer’s is the most common form of dementia, a condition forecast to affect 153 million people worldwide by 2050, and treatment options remain limited.
The stage three trial, a late-stage human study, spanned 13 countries including the UK. The findings were presented at the Clinical Trials on Alzheimer’s Disease conference in Boston.
AR1001 is a phosphodiesterase-5 inhibitor, a drug class that relaxes blood vessels and can increase blood flow. Viagra, used to treat erectile dysfunction, is in the same broad family of medicines.
Tara Spires-Jones, professor of neurodegeneration at the University of Edinburgh and a fellow at the Academy of Medical Sciences, said the results looked “very promising”. “This drug acts through boosting blood flow and likely also directly stimulating pathways in brain cells that promote learning and memory,” she said.
AriBio, the South Korean company that makes AR1001, said the 31% slowing was seen in patients who were not receiving other Alzheimer’s treatment. In a broader group that included patients taking other drugs, the tablet did not achieve statistically significant results.
Sheona Scales, director of research at Alzheimer’s Research UK, said the findings were “very encouraging” and called AR1001 “especially interesting” because it is an oral drug that takes a “different approach” from amyloid-targeting treatments. She added that the subgroup benefit was significant, but “this benefit was not significant across the overall trial group.”
Richard Oakley, associate director of research and innovation at Alzheimer’s Society, said the top-line results were “an exciting sign” of a possible new treatment for early Alzheimer’s disease. He said the once-daily tablet slowed decline in memory and thinking by nearly a third over one year, with side-effects reported as mostly mild to moderate.
The study cannot show from the reported top-line findings whether AR1001 would help patients already taking common Alzheimer’s symptom drugs. Oakley said that question needed further investigation and added that people should not take Viagra to try to treat Alzheimer’s.
Experts cited in the report said AR1001 would need further trials and scrutiny by scientific and drug-regulatory bodies before it could be prescribed for Alzheimer’s disease.
Source: news report, The Guardian Health, Nov. 18, 2026.
Atlas360 reports health research and does not provide medical advice.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- U.S. faces loss of measles elimination status after 5,412 cases
- Congo Ebola outbreak spreads to 8 provinces
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

